Cytokines of the interleukin-1 (IL-1) family, such as IL-1α/β and IL-18, have pleiotropic activities in innate and adaptive immune responses in host defense and diseases. Insight into their biological functions helped develop novel therapeutic approaches to treat human inflammatory diseases. IL-33 is an important member of the IL-1 family of cytokines and is a ligand of the ST2 receptor, a member of the IL-1 receptor family. However, the role of the IL-33/ST2 axis in tumor growth and metastasis of breast cancer remains unclear. Here, we demonstrate that IL-33 is a critical tumor promoter during epithelial cell proliferation and tumorigenesis in the breast. IL-33 dose-and time-dependently increased Cancer Osaka Thyroid (COT) phosphorylation via ST2-COT interaction in normal epithelial and breast cancer cells. The IL-33/ST2/COT cascade induced the activation of the MEK-ERK (MEK-extracellular signal-regulated kinase), JNK-cJun (cJun N-terminal kinase-cJun) and STAT3 (signal transducer and activator of transcription 3) signaling pathways, followed by increased AP-1 and stat3 transcriptional activity. When small interfering RNAs of ST2 and COT were introduced into cells, IL-33-induced AP-1 and stat3 activity were significantly decreased, unlike that in the control cells. The inhibition of COT activity resulted in decreased IL-33-induced epithelial cell transformation, and knockdown of IL-33, ST2 and COT in breast cancer cells attenuated tumorigenicity of breast cancer cells. Consistent with these observations, ST2 levels were positively correlated with COT expression in human breast cancer. These findings provide a novel perspective on the role of the IL-33/ST2/ COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment. Therapeutic approaches that target this pathway may, therefore, effectively inhibit carcinogenesis in the breast.
INTRODUCTION
Interleukin-33 (IL-33), a member of the IL-1 family, is a multifunctional cytokine released upon necrotic cell death; its secretion can also be induced in live cells under biomechanical stress conditions. 1 IL-33 is primarily expressed in non-hematopoietic cells, including fibroblasts, epithelial cells and endothelial cells, and is also present in cells of hematopoietic origin, particularly in macrophages and dendritic cells (DCs). 2 IL-33 was recently identified as a ligand for the orphan receptor ST2 (also known as IL-1R1), which was first identified in oncogene-or serumstimulated fibroblasts. 3 IL-33 binds a heterodimeric receptor complex consisting of ST2 and IL-1R accessory protein and induce the activation of numerous signaling proteins, including nuclear factor-κB (NF-κB), inhibitor of NF-κB-α, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 and cJun N-terminal kinase-1 (JNK1). 2 The IL-33/ST2 axis is a potent inducer of production of proinflammatory cytokines and chemokines by mast cells, particularly IL-1, IL-6, TNF (tumor necrosis factor) and CCL2 (chemokine (C-C motif) ligand 2), which have been implicated in both development and progression of cancer in some preclinical models. [4] [5] [6] However, the underlying molecular mechanisms and the specific signaling pathway of the IL-33/ST2 axis during tumor development remain to be elucidated.
The tumor-promoting effect of inflammation is now widely recognized and well understood. 7 Immune cells, which often infiltrate tumors and preneoplastic lesions, produce a variety of cytokines and chemokines that propagate a localized inflammatory response and also enhance the growth and survival of premalignant cells by activating transcription factors such as NF-κB. 8, 9 Interestingly, Cancer Osaka Thyroid (COT), also known as mitogen-activated protein kinase kinase kinase 8 (MAP3K8), and tumor progression locus 2 (TPL2), mediate cancer-associated inflammation in the tumor microenvironment, acting through the NF-κB-inducing kinase and inhibitor of NF-κB. 10 COT ablation in mice ameliorates the severity of a variety of inflammatory pathologies. 11 Early studies identified the cot gene as a target of provirus insertion in Moloney murine leukemia virus-induced T-cell lymphomas and mouse mammary tumor virus-induced mammary adenocarcinomas, yielding a truncated, C-terminus deletion product with transforming capacity. 12, 13 Although elevated levels of COT have been reported in certain tumor types, a detailed comparative evaluation of COT expression in human malignancy and normal tissue is lacking, and its physiological role in carcinogenesis remains enigmatic. Interestingly, ablation of COT attenuated human breast tumorigenesis induced by IL-17A and IL-22, which are proinflammatory cytokines produced from T helper 17 (Th17) cells, resulting from suppression of the ERK, JNK and STAT3 (signal transducer and activator of transcription 3) signaling pathways. 14, 15 In addition, COT has an important role in IL-12 production and Th cell differentiation, giving rise to the possibility that COT may be an interesting target for the development of drugs to treat chronic inflammatory diseases. 16 However, it is largely unknown whether COT is also involved in the IL-33/ST2 signaling pathway during tumor development.
In this study, we report that COT acts as a critical signal transducer in the IL-33/ST2 signaling axis. IL-33 markedly induced the phosphorylation of COT through increased interaction between ST2 and COT. Furthermore, IL-33-induced COT phosphorylation increased the activity of ERK1/2, JNK1/2 and STAT3, resulting in increased transcriptional activities of AP-1 and stat3. Ablation of COT effectively inhibited its role in epithelial cell transformation and tumorigenesis in the breast, demonstrating the critical oncogenic function of these IL-33-activated transcription factors.
RESULTS

IL-33 promotes anchorage-independent transformation and tumorigenesis in breast
To understand the pathological relevance of IL-33, an extracellular ligand for the ST2, 2 in breast tumorigenesis, immunohistochemistry was performed on human normal and breast cancer tissues using IL-33 and ST2 antibodies. Four of the 20 normal breast samples had a low amount of IL-33, whereas all of 20 breast cancer samples contained high amounts of IL-33 ( Figure 1a ). In contrast, 18 of the 20 normal breast samples had a low amount of ST2, whereas 13 of 20 breast cancer samples contained high amounts of ST2, indicating that ST2 expression was significantly increased in breast cancer (Figure 1a ). To further investigate the expression of IL-33 and ST2 proteins in breast cancer, we used immunoblotting to examine cells from the normal breast cells, MCF10A, and breast cancer cell lines, BT-474, MDA-MB231, MCF7 and SK-BR3. IL-33 and ST2 protein expressions were detected in all breast cancer cell lines ( Figure 1b ). Interestingly, ST2 expression in all breast cancer cell lines was higher than in normal breast cells ( Figure 1b ). To examine the effects of IL-33 on cell proliferation and anchorage-independent cell transformation, the 5-bromo-2deoxyuridine incorporation and soft agar assays were performed. We found that IL-33 treatment significantly and dose-dependently induced proliferation of JB6 Cl41 cells, in which IL-33 and ST2 were normally expressed ( Figure 1c ). Furthermore, IL-33 treatment significantly increased not only colony numbers but also colony sizes in JB6 Cl41 cells in a dose-dependent manner (Figure 1d ). To investigate the environmental effects of IL-33 on production of proinflammatory cytokines, IL-6, MCP-1 and TNF-α levels were analyzed in culture supernatant of IL-33-stimulated MCF7 and MDA-MB231 cells. IL-33 treatment led to a significant increase of IL-6 and MCP-1, but not TNF-α, in culture supernatant of MCF7 and MDA-MB231 cells (Supplementary Figure S1 ). However, the culture supernatant of IL-33-stimulated cells did not influence proliferation of MCF7 and MDA-MB231 cells, whereas IL-33 treatment significantly induced the proliferation of MCF7 and MDA-MB231 cells (Supplementary Figure S2 ). The effects of IL-33 on tumor development in vivo were studied in a syngeneic mouse 4T1 breast tumor metastasis model. IL-33 treatment significantly induced proliferation of 4T1 cells in a dose-dependent manner, in which IL-33 and ST2 were normally expressed ( Figure 1e ). Furthermore, representative tumor images demonstrated that IL-33 significantly induced mammary gland tumor development ( Figure 1f ). ST2 mediates IL-33-induced COT phosphorylation via the interaction of ST2 with COT To investigate the relationship between ST2 and COT in human breast cancer, we performed immunohistochemistry using specific antibodies against human ST2 and COT in human breast cancer tissues. Five of the seven breast cancer samples that showed low amounts of ST2 presented with lower expression COT, whereas all 13 breast cancer samples that contained a high amount of ST2 correspondingly had higher expression of COT (Figure 2a ). To examine whether COT is a critical signal transducer in the IL-33 signaling pathway, we first tested whether ST2 interacts with COT in cells. Reciprocal immunoprecipitation/immunoblotting using anti-Myc and anti-ST2 antibodies showed that endogenously expressed ST2 interacted with Myc-COT in vitro ( Figure 2b ). Previously, we reported that COT could be phosphorylated on the Ser400 residue of its C terminus by immune cytokines such as IL-17A and IL-22. 14, 15 Thus, this study examined the possibility that mutation of the Ser400 residue at the COT carboxyl terminus affects COT's interaction with ST2. To determine the site responsible for COT's interaction with ST2, we mutated the Ser400 of COT to Ala and investigated the ability of this nonphosphorylated mutant to bind to ST2 in immunoprecipitation/ immunoblotting analyses. The results showed that mutation of the Ser400 site in COT led to a significant loss of binding between COT and endogenous ST2 ( Figure 2c ). In addition, endogenous ST2 interacted with COT in IL-33-stimulated cells but not in unstimulated cells (Figure 2d ). To further determine whether IL-33 phosphorylates COT, JB6 Cl41 cells were treated with IL-33, and immunoblotting was performed using a specific antibody for phospho-COT (Ser400). The results showed that IL-33 markedly induced phosphorylation of COT in a dose-and time-dependent manner (Figure 2e ). However, knockdown of ST2 suppressed IL-33-induced phosphorylation of COT ( Figure 2f ). Given the positive correlation between ST2 and COT abundance in human breast cancer tissues and the phosphorylation-dependent interaction between ST2 and COT, we next examined the effect of IL-33 on the phosphorylation of COT in MDA-MB231 and MCF7 cells. The results showed that IL-33 markedly induced the phosphorylation of COT in both cell types ( Figure 2g ).
COT mediates the MEK1/2-ERK1/2 and JNK1/2-cJun signaling pathways induced by IL-33 Given the role of COT as an important signal transducer of IL-33/ST2 axis, we examined whether COT might regulate the IL-33-induced MEK1/2-ERK1/2 and JNK1/2-cJun signaling pathways. The results showed that IL-33 induced phosphorylation of MEK1/2 and ERK1/2 in a dose-and time-dependent manner (Figures 3a and b ), as well as JNK1/2 and cJun ( Figures 3c and d ). Furthermore, treatment with TKI (Tpl2 kinase inhibitor), a COT inhibitor, inhibited the IL-33-induced phosphorylation of MEK1/2, ERK1/2, JNK1/2 and cJun ( Figure 3e ). Similarly, PD98059, a specific MEK1/2 inhibitor, and SP600125, a specific JNK inhibitor, also inhibited the IL-33-induced phosphorylation of ERK1/2 and cJun, respectively ( Figure 3f ), thus suggesting that COT mediates the IL-33-induced MEK1/2-ERK1/2 and JNK1/2-cJun signaling pathways through COT activation in JB6 Cl41 cells. Consistent with these results, we observed that MEK1/2, ERK1/2, JNK1/2 and cJun were phosphorylated by IL-33 in MDA-MB231 and MCF7 cells (Figures 3g and h), suggesting that COT might have an important role in IL-33-induced epithelial cell proliferation and mammary tumorigenesis.
COT mediates STAT3 phosphorylation via its interaction with STAT3 STAT3 is a transcription factor that is activated by the actions of many autocrine and paracrine growth factors, including IL-6 and epidermal growth factor, in human cancers, 17, 18 suggesting that IL-33 may have a regulatory role in STAT3 activation. Given the ST2-and COT-specific interaction induced by IL-33, it is important to understand whether COT mediates IL-33-induced STAT3 phosphorylation. The interaction detected between Myc-COT and STAT3 in in vitro binding assays (Figures 4a and b ) supports the hypothesis that STAT3 is a possible COT target. In addition, endogenous COT interacts with STAT3 in IL-33-stimulated cells but not in unstimulated cells (Figure 4c ). To determine whether IL-33induced STAT3 activation is mediated by COT, we first examined the IL-33-induced phosphorylation of STAT3 in JB6 Cl41 cells. The results showed that IL-33 dose-and time-dependently increased the phosphorylation of STAT3 in JB6 Cl41 cells (Figures 4d and e ). In addition, the phosphorylation of STAT3 induced by IL-33 was suppressed in small interfering RNA (siRNA)-ST2-transfected cells compared with siRNA-control-transfected cells (Figure 4f ). Furthermore, the knockdown of COT inhibited the IL-33-induced phosphorylation of STAT3 ( Figure 4g ). TKI also inhibited the IL-33-induced phosphorylation of STAT3 in a dose-dependent manner (Figure 4h ). Consistent with these results, we observed that STAT3 phosphorylation was induced by IL-33 in MDA-MB231 and MCF7 cells (Figure 4i ), indicating that COT positively regulates the STAT3 signaling pathway induced by IL-33 in human breast cancer cells.
COT is required for IL-33-induced AP-1 and STAT3 activation The AP-1 transcription factor is a dimeric complex of homodimers or heterodimers of Jun, Fos, activating transcription factor and musculoaponeurotic fibrosarcoma protein family members that are activated by the mitogen-activated protein kinase signaling pathway. 19, 20 To determine the effects of IL-33 on AP-1 activity, we first examined the effects of IL-33 on the c-fos and c-jun promoter. The transcriptional activity of c-fos and c-jun was significantly increased by treatment with IL-33 in JB6 Cl41 cells in a dose-dependent manner (Figures 5a and b ). In addition, treatment with IL-33 was found to significantly induce AP-1 transactivation in JB6 Cl41 cells (Figure 5c ). Given the increased phosphorylation of STAT3 induced by IL-33, we next examined the effect of IL-33 on the transcriptional activity of STAT3 in JB6 Cl41 cells using a stat3 reporter gene assay. The results showed that IL-33 treatment significantly enhanced stat3 transcriptional activity ( Figure 5d ). To further confirm that COT regulates the AP-1 and Immunoblotting analysis was performed using specific antibodies against the corresponding proteins. The figure is representative of at least three separate experiments that yielded similar results. (c) Left, expression levels of IL-33 and ST2 in MDA-MB231 cells or JB6 Cl41 cells; right, JB6 Cl41 cells were seeded, treated with different concentrations of IL-33 for 24 h and then cell proliferation was estimated using a 5-bromo-2-deoxyuridine (BrdU) assay. (d) JB6 Cl41 cells were exposed to various concentrations of IL-33 in soft agar matrix, and incubated at 37°C in a 5% CO 2 atmosphere for 14 days. (e) Left, expression levels of IL-33 and ST2 in MDA-MB231 cells or 4T1 cells; right, 4T1 cells were seeded, treated with different concentrations of IL-33 for 48 h and then cell proliferation was estimated using a BrdU assay. (f) 4T1 cells were injected into the mammary gland of BALB/c mice in the presence or absence of 250 ng/ml IL-33, and allowed to grow until tumors formed (14 days). Data in (c-f) are represented as mean ± s.e.m. from one experiment representative of three independent experiments performed. *P o0.05. stat3 transcriptional activity induced by IL-33, we assessed IL-33induced AP-1 and stat3 activity in the presence or absence of TKI in JB6 Cl41 cells. As expected, TKI treatment inhibited the IL-33induced AP-1 and stat3 activity in JB6 Cl41 cells (Figures 5e and f). To further determine the effects of COT knockdown on stat3 transcriptional activation, MDA-MB231 cells were transfected with siRNA-COT, and then exposed to IL-33. Consistent with a potential positive role for COT in the IL-33-induced MEK-ERK, JNK-cJun and STAT3 signaling pathways, depletion of endogenous COT in MDA-MB231 cells suppressed the IL-33-induced phosphorylation of ERK1/2, cJun and STAT3 (Figure 5g ). More importantly, depletion of COT in MDA-MB231 cells profoundly reduced the AP-1 and stat3 activity induced by IL-33, compared with the untreated control group (Figures 5h and i ), suggesting that IL-33-induced AP-1 and stat3 transcriptional activity is mediated by COT signaling.
An IL-33/ST2/COT axis promotes epithelial cell transformation and breast mammary tumorigenesis To investigate whether COT and STAT3 are essential for IL-33induced epithelial cell transformation, we first examined the effect of TKI and WP1066 in JB6 Cl41 cells on IL-33-induced transformation. The results showed that TKI and WP1066 treatment significantly inhibited the IL-33-induced transformation of JB6 Cl41 cells (Figure 6a ). Given the ability of IL-33 to induce epithelial cell transformation via the interaction between ST2 and COT, we wondered whether inhibition of this signaling pathway contributes to suppression of breast tumorigenesis. Compared with the control group, knockdown of ST2, IL-33 and COT in MCF7 cells significantly attenuated the number of colonies in soft agar (Figure 6b ). Next, we studied the correlation between COT activity and IL-33 on tumorigenicity of MCF7 cells using a soft agar assay. cells expressing endogenous ST2 with Myc-COT were subjected to immunoprecipitation with anti-myc or anti-ST2 antibodies, followed by immunoblotting (IB) with anti-ST2 or anti-Myc antibodies. Normal IgG antibody was used as a negative control (ctrl) for immunoprecipitation. (c) JB6 Cl41 cells were transfected with COT-WT or COT-S400A, and then subjected to immunoprecipitation with anti-Myc, followed by immunoblotting with anti-ST2 antibodies. (d) JB6 Cl41 cells were starved for 24 h and stimulated with 25 ng/ml IL-33 for the indicated time. Immunoprecipitation was performed to precipitate endogenous COT (upper) or ST2 (lower), and then IB analysis was performed using anti-ST2 (upper) or anti-COT (lower) antibodies, respectively. (e) JB6 Cl41 cells were serum-starved for 24 h, treated with the indicated doses of IL-33 for 30 min (left) or 25 ng/ml IL-33 for the indicated times (right), harvested, lysed and IB. (f) JB6 Cl41 cells were transfected with siRNA-ST2. After 48 h, cells were serum-starved for 24 h, treated or not treated with 25 ng/ml IL-33 for 30 min, harvested, lysed and IB. (g) MDA-MB231 or MCF7 cells were serum-starved for 24 h, treated with or without the indicated doses of IL-33 for 30 min, harvested, lysed, IB. The figures are representative of at least three separate experiments that yielded similar results. WT, wild type.
The results showed that COT knockdown greatly inhibited colony formation of MCF7 cells (Figure 6c , top right). Consistent with these results, depletion of COT in MCF7 cells profoundly reduced IL-33-induced tumor growth, compared with the untreated control group (Figure 6c, bottom right) . The effects of COT on IL-33induced tumor development in vivo were studied in a syngeneic nude mice model with 4T1 metastatic mouse breast carcinoma cells. Representative tumor images demonstrated that IL-33 significantly induced mammary gland tumor development, whereas treatment with TKI significantly inhibited mammary gland tumor development, suggesting that COT might have an important role in IL-33-induced mammary tumorigenesis (Figure 6d ). Knowing that COT activates STAT3 via its interaction with STAT3, we also examined the effects of WP1066 on IL-33induced tumor development in vivo. The results showed that STAT3 inhibition greatly suppressed mammary gland tumor development (Figure 6d) , indicating that the COT-STAT3 signaling pathway has a pivotal role in breast tumorigenesis. To better determine the role of IL-33 on the mammary tumorigenesis, we established human IL-33 stably transfected 4T1 cell lines (4T1/Myc-IL-33) and evaluated the tumorigenicity of IL-33overexpressing cells in nude mice model. The results showed that IL-33 overexpression significantly enhanced mammary gland tumor development compared with control in nude mice (Figure 6e , top right panels). In addition, compared with the control group, knockdown of human IL-33 in 4T1/Myc-IL-33 cells significantly attenuated the tumor growth in nude mice (Figure 6e , middle right panels).
DISCUSSION
Although cell-autonomous events, such as proliferation and death evasion, control tumor development, the tumor microenvironment also makes a major contribution and influences the physiology of malignant cells. 21 Nearly all tumors contain inflammatory and immune cells, such as DCs, macrophages and (c and d) JB6 Cl41 cells were serum-starved for 24 h, treated with the indicated doses of IL-33 for 30 min as in (c) or 25 ng/ml IL-33 for the indicated times as in (d), harvested, lysed and immunoblotted. (e) JB6 Cl41 cells were serum-starved for 24 h, pretreated with the indicated concentrations of TKI for 2 h, exposed to 25 ng/ml IL-33 for 30 min, harvested, lysed and immunoblotted. (f) JB6 Cl41 cells were serum-starved for 24 h, and then treated with either PD98059 (upper) or SP600125 (lower). At 1 h after pretreatment, cells were exposed to 25 ng/ml IL-33 for 30 min, harvested, lysed and immunoblotted. (g and h) MDA-MB231 and MCF7 cells were serum-starved for 24 h, treated with or without the indicated doses of IL-33 for 30 min, harvested, lysed and immunoblotted. The figures are representative of at least three separate experiments that yielded similar results. lymphocytes, which produce cytokines and other factors that promote tumor growth and survival. 7, 8, 22 The most obvious tumorpromoting role of immune cells is manifested in inflammationassociated cancers, where tumors arise and grow at sites of chronic inflammation. Here, we provide the first direct evidence that IL-33 leads to the activation of COT via its interaction with ST2, which results in the induction of neoplastic cellular transformation through its downstream AP-1 and STAT3 signaling pathways. Combined with our increasing understanding of the IL-33/ST2 signaling pathway, this work highlights how COT regulates IL-33-induced tumorigenesis.
IL-33 is a member of the IL-1 cytokine family, originally described as a nuclear protein in cerebral arteries 23 and later as NF-HEV, an NF expressed in human high endothelial venules in secondary lymphoid organs. 24 Recently, IL-33 was identified as the ligand for the orphan receptor, ST2 (IL-1RL1). 25 ST2 molecules are members of the IL-1 receptor family and exist in two forms: a transmembrane full-length form (ST2L) and a soluble secreted form (sST2) due to differential splicing of ST2 mRNA. 26 ST2 associates with IL-1R accessory protein to form an IL-33 receptor (IL-33R1), and IL-33 signals via this heterodimer. 2 The binding of IL-33 to ST2 results in the recruitment of MyD88, IRAK1 and IRAK4 to the receptor complex in the cytoplasmic region of ST2, 27 which induces activation of various signaling proteins, including NF-κB, inhibitor of NF-κB-α, ERK1/2, p38 and JNK1/2, leading to the induction of the inflammatory mediators IL-1β, IL-3, IL-6, TNF, IL-5 and IL-13. 5,28,29 Furthermore, TNF receptor-associated factor 6 (TRAF6) has been shown to be a critical adaptor molecule in both the IL-1 and IL-33 signaling pathways. 30, 31 IL-33 rapidly induces the formation of an ST2L complex containing IRAK; however, the absence of TRAF6 abolishes the recruitment of IRAK to ST2L. 31 Consequently, the IL-33-induced activation of p38, JNK and NF-κB is completely inhibited in TRAF6-deficient MEFs. 31 Interestingly, ST2 deletion attenuates tumor growth and metastasis in 4T1 breast tumor model and IL-33 promotes breast cancer progression through increased intratumoral accumulation of immunosuppressive cells and by diminishing innate antitumor immunity. 32, 33 Here, a demonstration of the clinical relevance of IL-33/ST2 axis was provided by our results in breast cancer patients. This analysis revealed that the prognostic value of IL-33, ST2 and COT levels is readily detected in human breast cancer tissues. Furthermore, ST2 levels were positively correlated with COT levels in breast cancer tissues, indicating that the IL-33/ST2 axis contributed to breast carcinogenesis via COT activation. Furthermore, ST2 directly interacts with wild-type COT, but not with its mutant S400A. Indeed, IL-33 increases the interaction between ST2 and COT, suggesting that COT is an important signal transducer for the IL-33/ST2 signaling pathway. As a result, IL-33 strongly induced phosphorylation of COT at Ser400, followed by the activation of the MEK-ERK and JNK-cJun signaling pathways. In addition, the knockdown of ST2 lowered IL-33-induced COT phosphorylation, indicating that COT activation depends on the IL-33/ST2 signaling axis. Moreover, TKI, PD98059 and SP600125, which are COT, MEK and JNK inhibitors, respectively, strongly suppressed the IL-33-induced MEK-ERK and JNK-cJun signaling pathways. Overall, these data indicate that COT functions as an important mediator of the IL-33-ST2 signaling pathway, which contributes to breast carcinogenesis.
The pathway from Ras through Raf and MEK (mitogen-activated protein kinase and ERK kinase) to ERK/MAPK (ERK-regulated kinase/mitogen-activated protein kinase) regulates many fundamental cellular processes that govern that govern cell transformation, differentiation, proliferation and survival. 34 Interestingly, lipopolysaccharide, a component of Gram-negative bacteria, and the proinflammatory cytokines TNFα and IL-1 do not require Raf, but instead require a distinct COT to promote tumor development and growth. [35] [36] [37] In addition, the neoplastic transforming activity of COT results from the coordinated activation of chromatin remodeling by histone H3, which ultimately converges on the regulation of c-fos transcriptional activity, followed by AP-1 transcriptional activity. 38 AP-1 is a major transcription factor in epithelial cell transformation and tumor development induced by various tumor promoters, such as epidermal growth factor and 12-O-tetradecanoylphorbol 13-acetate. 39 Despite the vital role of COT in chronic inflammatory diseases and tumor development, the precise mechanisms that regulate the IL-33 signaling pathway in epithelial cell transformation and tumorigenesis in the breast have not yet been well explored. The data presented in this report show that the IL-33/ST2/COT pathway promotes c-fos and c-jun promoter activity, resulting in the induction of AP-1 activity in JB6 Cl41 cells. The silencing of COT, and also the inhibition of COT activity by TKI, markedly suppressed IL-33-induced AP-1 activity in Figure 5 . Effects of inhibition of COT on IL-33-induced AP-1 and stat3 promoter activity. (a-d) JB6 Cl41 cells were co-transfected with a luciferase reporter, c-fos-luc (a), c-jun-luc (b), AP-1-luc (c) or stat3-luc (d) and the pRL-TK vector. At 30 h after transfection, cells were serumstarved for 24 h, and then treated with the indicated doses of IL-33 for 24 h. (e and f) JB6 Cl41 cells were co-transfected with a luciferase reporter, AP-1-luc (e) or stat3-luc (f), and the pRL-TK vector, respectively. After 30 h, cells were serum-starved for 24 h and then treated with 25 ng/ml IL-33 in the presence or absence of the indicated doses of TKI for 30 h. (g) MDA-MB231 cells were transfected with siRNA-control (ctrl) or siRNA-COT. After 48 h, cells were serum-starved for 24 h, treated or not treated with 25 ng/ml IL-33 for 30 min, harvested, lysed and immunoblotted. The figure is representative of at least three separate experiments that yielded similar results. (h and i) MDA-MB231 cells were co-transfected with a luciferase reporter, AP-1-luc (h) or stat3-luc (i), and siRNA-COT. After 30 h, cells were serum-starved for 24 h and then treated with 25 ng/ml IL-33 for 24 h. Data in (a-f, h and i) are represented as mean ± s.e.m. from one experiment representative of three independent experiments performed. *P o0.05.
JB6 Cl41 and MDA-MB231 cells. These findings, coupled with our recently published work showing that COT conveys oncogenic signals to promote aggressiveness in human breast cancers, indicate that COT may have an essential role in epithelial cell transformation and tumor development in the breast. Interestingly, ST2 levels were positively correlated with COT expression in breast cancer tissues. These results define an IL-33/ST2 signaling axis that conveys an oncogenic signal to promote aggressiveness in human breast cancers through the induction of COT activity. Consistent with these observations, our results also showed that knockdown of IL-33, ST2 and COT decreased the tumorigenicity of MCF7 cells, suggesting that COT might be an important Figure 6 . Effects of the ST2/COT axis on IL-33-induced epithelial cell transformation and breast mammary tumorigenesis. (a) JB6 Cl41 cells were treated with 50 ng/ml IL-33 with/without treatment of 10 μM TKI or 10 μM WP1066 as indicated in soft agar matrix, and incubated at 37°C in a 5% CO 2 atmosphere for 14 days. (b) MCF7 cells were transfected with siRNA-ST2, siRNA-IL-33 or siRNA-COT. At 48 h after transfection, cells were treated with/without 50 ng/ml IL-33 in soft agar matrix and incubated at 37°C in a 5% CO 2 atmosphere for 14 days. (c) MCF7 cells were transfected with either siRNA-control (ctrl) or siRNA-COT. At 48 h after transfection, cells were treated with/without 50 ng/ml IL-33 in soft agar matrix and incubated at 37°C in a 5% CO 2 atmosphere for 14 days. (d) 4T1 cells were injected into the mammary gland of BALB/c mice in the presence or absence of 250 ng/ml IL-33 with 100 μM TKI or WP1066, respectively, and allowed to grow until tumors formed (14 days) . STAT3 is constitutively activated in more than 50% of primary breast tumors and tumor-derived cell lines. [40] [41] [42] Clinical studies have demonstrated that elevated levels of tyrosinephosphorylated STAT3 in patients with stage II breast cancer are correlated with an incomplete response to neoadjuvant chemotherapy. 43 The evidence that activated STAT3 participates in a causal manner in breast tumorigenesis is based on studies from cell lines expressing high levels of phosphorylated STAT3. Inhibiting or removing STAT3 leads to increased apoptosis, chemosensitivity and decreased angiogenesis both in cell culture and in xenograft models. 40, 44 Furthermore, the expression of a constitutively active form of STAT3 (STAT3C) in immortalized human breast epithelial cells mediates de novo tumorigenesis, demonstrating the sufficiency of this transcription factor in promoting cellular transformation. 45 STAT3 activation can occur through the actions of many autocrine and paracrine growth factors, including IL-6, epidermal growth factor, platelet-derived growth factor, heregulin, vascular endothelial growth factor, hepatocyte growth factors and the Src non-receptor tyrosine kinase, leading to the prediction that it would be phosphorylated in breast cancer via these multiple, redundantly acting growth factors. [46] [47] [48] However, little is known about whether and how STAT3 activity is regulated by IL-33/ST2 signaling during tumor development. Here, we provide that endogenous COT interacts with STAT3 in an IL-33-dependent manner. Moreover, IL-33 strongly induced phosphorylation of STAT3 at Tyr 705, indicating that a homodimer of phosphorylated STAT3 induced by IL-33 then translocates to the nucleus and induces the transcription of several target genes promoting proliferation, cell growth and the inhibition of apoptosis. In addition, the knockdown of ST2 as well as COT decreased IL-33-induced STAT3 phosphorylation. The treatment with TKI, a COT inhibitor, strongly suppressed IL-33induced STAT3 phosphorylation, resulting from the inhibition of COT activity, indicating that COT functions as an important mediator of the IL-33/ST2 signaling pathway to induce stat3 transcriptional activity. This study documents a previously unknown role of IL-33 in human breast cancer by displaying its promotional role in proliferation, cell survival, transformation and tumor development. Moreover, these results collectively reveal COT as an attractive therapeutic target in the tumor microenvironment, inhibition of which could potentially attenuate the aggressiveness of breast cancer. Hence, our study not only reveals a novel mechanism underlying IL-33 activity but also provides a novel treatment strategy against metastatic breast cancer.
MATERIALS AND METHODS
Cell lines and establishment of stable cell lines JB6 Cl41 mouse epidermal cells were maintained in Eagle's minimal essential medium supplemented with 5% fetal bovine serum. MCF7, MDA-MB231 and 4T1 breast cancer cells were grown in Dulbecco's modified Eagle's medium, Eagle's minimal essential medium and Roswell Park Memorial Institute medium (RPMI) supplemented with 10% fetal bovine serum, respectively. All cell lines were cultured and maintained at 37°C in humidified air containing 5% CO 2 . For establishment of IL-33 stably overexpressing cell lines, human IL-33 expression plasmid, pCMV/Myc-IL-33, was transfected into mouse 4T1 cells. At 48 h after transfection, cells were cultured in medium containing 600 μg/ml of neomycin. Each colony that grew after G418 selection was picked and expended. We designated the 4T1 cells transfected with the IL-33 expression vector as 4T1/Myc-IL-33 cells.
Reagents and antibodies
Recombinant human IL-33 was obtained from R&D Systems (Minneapolis, MN, USA). The COT inhibitor (TKI, 4-(3-chlor-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-1, 7-naphthylridine)) and WP1066, PD98059 and SP600125 were purchased from Calbiochem-Novabiochem (San Diego, CA, USA). The phospho-specific and total antibodies against MEK1/2, ERK1/2 JNK1/2, and STAT3 and the phospho-specific antibodies against COT and cJun (Ser 63) were acquired from Cell Signaling Technology Inc. (Beverly, MA, USA); antibody against ST2 was purchased from Abcam (Cambridge, MA, USA); and cJun, COT and mouse IgG were acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-c-Myc antibody and anti-ST2 were purchased from Sigma-Aldrich (St Louis, MO, USA). The anti-IL-33 antibody was purchased from Millipore (Billerica, MA, USA).
Construction of mammalian expression and siRNAs
The WT and mutants (S400A) of the pRK-Myc-COT plasmids were provided by Warner C Greene (University of California, San Francisco, CA, USA). The human IL-33 expression plasmid, pCMV/Myc-IL-33, was purchased from OriGene Technology Inc. (Rockville, MD, USA). IL-33 (accession number: NM_001199640), ST2 (accession number: NM_010743) and COT (accession number: NM_005204) were silenced by transfecting the ON-TARGET plus siRNA SMART pool-specific or nonspecific control pool double-stranded RNA oligonucleotides (Dharmacon, Chicago, IL, USA) using Lipofectamine 2000 (Life Tech., Grand Island, NY, USA).
Tumor samples
The breast tissues that were selected for immunohistochemical staining were collected from a breast cancer group of 60 patients (age range: 42-72 years). The normal breast group included infiltrating mammary duct carcinoma patients who had undergone mastectomy with adjuvant hormone therapy and had no subsequent local recurrence or metastasis within 5 years, and the breast cancer group included mammary infiltrating duct carcinoma patients who had undergone mastectomy with adjuvant hormone therapy and lapsed into a subsequent bone metastasis. Informed consent was obtained from all the patients, and research protocols were approved by the ethics committee of Chosun University Hospital (Gwangju, South Korea).
Immunohistochemical staining analysis
All tumors investigated in the study were tested using the ST2, IL-33 and COT mouse monoclonal antibodies. Immunolocalization for each antibody was performed using a Polink-2 HRP Plus mouse diaminobenzidine detection system (Golden Bridge International, Mukilteo, WA, USA), according to the supplier's protocol. Slides were incubated for 1 h with anti-IL-33 and anti-ST2 antibodies and overnight with anti-COT antibody in a moist chamber at 37°C. Instead of a primary antibody, normal goat serum was used in the negative control. Distinct cytoplasmic staining for COT, ST2 and IL-33 were considered to indicate positive immune reactivity.
Tumorigenicity assay in nude mice
Six-week-old female BALB/c mice (18-20 g) were obtained from Samtako Co. (Osan, South Korea), acclimatized for 1 week and maintained in a clean room at the College of Pharmacy, Chosun University. The protocols for the animal studies were approved by the Animal Care Committee of Chosun University. Mice were randomly divided into two or four groups of 20 animals each, and 4T1 cells, control-transfected 4T1 cells (4T1/mock), IL-33-transfected 4T1 cells (4T1/Myc-IL-33) were trypsinized, washed with phosphate-buffered saline, resuspended in phosphate-buffered saline and adjusted to a concentration of 1 × 10 6 /100 μl in phosphate-buffered saline. Later, the cell suspensions were injected into the mammary gland of the mice in the presence or absence of IL-33 and 100 μM TKI and/or WP1066 and then allowed to grow until the formation of tumors. The tumor volume was calculated using the formula: V = (ab 2 )/2, in which 'a' was the longest diameter and 'b' was the shortest diameter of the tumor.
Statistical analysis
Fisher's exact test with two-sided probability values (Po0.001) was used to analyze correlations between IL-33, ST2 and COT in breast cancer patients. Data from the 5-bromo-2-deoxyuridine incorporation assay, the reporter gene assay and the soft agar assay were analyzed using unpaired t-tests, and P-values of o0.05 were considered significant. Statistical calculations were carried out with Prism 4.0 for Macintosh (GraphPad Software Inc., La Jolla, CA, USA). Results are expressed as the mean ± s.e.m. of triplicate measurements of three independent experiments.
